跳至主要内容
临床试验/NCT00231244
NCT00231244已完成3 期

Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry

Cordis Corporation2 个研究点 分布在 1 个国家目标入组 252 人开始时间: 2002年3月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
252
试验地点
2
主要终点
The primary endpoint of this study is a composite of Target Vessel Failure (TVF) defined as target vessel revascularization, myocardial infarction or cardiac death at 30 days, 6mo, 12mo, 2, 3, 4, and 5 years.

研究概览

简要总结

The objective of this study is to allow treatment with the sirolimus-eluting Bx VELOCITYTM stent in patients with a serious disease or condition for which there is no generally acceptable alternate treatment available.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or non-pregnant female patient minimum 18 years of age
  • There is no alternative treatment for this patient as determined by the treating physician and an uninvolved cardiac surgeon;
  • Target lesion is 2.50mm and 3.50mm in diameter (visual estimate);
  • Target lesion is 45mm in length (visual estimate), treated with a maximum of three 18 mm stents;

排除标准

  • There is currently another method of treatment for the patient, including coronary artery bypass surgery (CABG) or brachytherapy;
  • The study target lesion has definite or possible thrombus present by angiographic criteria.

结局指标

主要结局

The primary endpoint of this study is a composite of Target Vessel Failure (TVF) defined as target vessel revascularization, myocardial infarction or cardiac death at 30 days, 6mo, 12mo, 2, 3, 4, and 5 years.

时间窗: 30 days, 6mo, 12mo, 2, 3, 4, and 5 years

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验